Loading...

Gabrielle Agin-Liebes, PhD

Title(s)Postdoctoral Scholar, Psychiatry
SchoolSchool of Medicine
Address
Phone--
ORCID ORCID Icongagin-liebes Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Gabby is a clinical psychologist and a National Institute on Drug Abuse T32 Research Fellow in Substance Use Disorders Treatment and Services Research at UCSF. Her work draws on quantitative and qualitative methodologies to explore transdiagnostic psychological mechanisms, including emotion regulation, metacognition, and attachment, underlying the therapeutic outcomes in treatments of mood, anxiety and substance use disorders. At UCSF, Gabby is conducting mechanistic research aimed at improving treatment strategies for opioid use disorder and chronic pain, with a focus on understanding approach-avoidance tendencies involved in the etiology of these co-occurring disorders. She is also exploring the use of behavioral paradigms (delay discounting), cognitive training (approach bias modification) and therapeutic interventions, including psilocybin-assisted and mindfulness-based therapies, to help prevent relapse and restructure dysregulated motivational reward systems involved in addiction.

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacology & Translational Science. 2021. Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. View Publication.
    2. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science. 2021. Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. View Publication.
    3. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2020; 4(57):354-88. Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, Guss J, Bossis A, Ross S.
    4. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020. Anderson BT, Danforth A, Daroff R, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley J, Mitchell J, Woolley J.
    5. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Oct; 27:100538. Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. PMID: 33150319.
      View in: PubMed   Mentions:
    6. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020 02; 34(2):155-166. Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. PMID: 31916890.
      View in: PubMed   Mentions: 7     Fields:    
    7. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. 2018; 9:256. Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. PMID: 29666578.
      View in: PubMed   Mentions:
    8. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol. 2017; 5(57):488-519. Swift TC*, Belser AB*, Agin-Liebes G*, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S. [*denotes co-first authorship].
    9. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 12; 30(12):1165-1180. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. PMID: 27909164.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    10. The child and adolescent mental health studies program (CAMS) at New York University. Neuropsychiatrie de l'enfance et de l'adolescence. 2012; 5(60):296. Shatkin J, Agin-Liebes G. .
    Gabrielle's Networks
    Concepts (23)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑